Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Praziquantel paediatric formulation - Pediatric Praziquantel Consortium

Next Previous
Drug Profile

Praziquantel paediatric formulation - Pediatric Praziquantel Consortium

Alternative Names: arpraziquantel - Pediatric Praziquantel Consortium; L-praziquantel; L-praziquantel orodispersible; L-PZQ; L-PZQ ODT; MSC-1028703; MSC-1028703A; MSC-2499550A; PZQ ODT; Rac-PZQ ODT; Racemate PZQ ODT

Latest Information Update: 18 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pediatric Praziquantel Consortium
  • Developer Merck KGaA; Pediatric Praziquantel Consortium
  • Class 3-ring heterocyclic compounds; Anthelmintics; Cyclohexanes; Isoquinolines; Pyrazines; Small molecules
  • Mechanism of Action TRPM cation channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Schistosomiasis

Most Recent Events

  • 04 Mar 2025 Clinical trials in Schistosomiasis (In children, In volunteers) in Uganda (PO)
  • 27 Dec 2023 Merck KGaA announces intention to submit regulatory application of praziquantel paediatric formulation for Schistosomiasis
  • 15 Dec 2023 CHMP adopts a positive opinion for arpraziquantel for the treatment of Schistosomiasis (In children, In infants) in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top